


APPROACHES TO THE FULLY FUNCTIONALIZED DEF RING SYSTEM OF RISTOCETIN A VIA HIGHLY SELECTIVE RUTHENIUM-PROMOTED S_NAr REACTION

Anthony J. Pearson* and Jung-Nyoung Heo



Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106

ajp4@po.cwru.edu

SUPPLEMENTARY MATERIAL

Experimental

(S)-N-(Benzylloxycarbonyl)-1-(3-benzylxy-5-methoxy-4-methyl-phenyl)-2-hydroxyethylamine (11). To a solution of benzyl carbamate (380 mg, 2.51 mmol, 3.1 equiv) in 1-propanol (5 mL) was added an aqueous solution of NaOH (99 mg, 2.47 mmol, 3.05 equiv) in H₂O (6 mL), followed by *t*-butyl hypochlorite (268 mg, 2.47 mmol, 3.05 equiv). After 5 min a solution of (DHQ)₂PHAL (32 mg, 0.04 mmol, 5 mol %) in 1-propanol (4 mL) was added to the above solution. Styrene **10** (206 mg, 0.81 mmol) dissolved in ethyl ether (3 mL) was then added, followed by K₂OsO₂(OH)₄ (12 mg, 0.032 mmol, 4 mol %). The resulting emulsion was stirred at rt for 1h until the mixture became a clear light yellow solution. The reaction was cooled to 0 °C and quenched with saturated Na₂SO₃ solution (10 mL) and further stirred for 15 min. The mixture was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with water (15 mL), brine (15 mL), dried (MgSO₄), and concentrated to provide the crude mixture of regioisomers (1°/2° alcohol = 4/1). Flash chromatography (2:3 EtOAc/hexanes) gave 227 mg (66%) of the desired 1° alcohol **11** as a colorless solid and 57 mg (17%) of the 2° alcohol. For 1° alcohol: mp 115-118 °C; R_f = 0.20 (2:3 EtOAc/hexanes); [α]²⁵_D +25.5 (c 1.0, CHCl₃); ¹H NMR (CDCl₃, 300 MHz) δ 7.44-7.31 (m, 10H), 6.52 (s, 1H), 6.47 (s, 1H), 5.53 (bs, 1H), 5.11 (s, 2H), 5.04 (s, 2H), 4.77 (s, 1H), 3.83 (d, 2H, J = 3.9 Hz), 3.80 (s, 3H), 2.13 (s, 3H), 2.02 (bs, 1H); ¹³C NMR (CDCl₃, 50 MHz) δ 158.8, 157.7, 156.6, 137.8, 137.4, 136.3, 128.6, 128.3, 127.9, 127.3, 114.8, 103.4, 102.2, 70.4, 67.2, 66.6, 57.7, 55.8, 8.5; IR (KBr) 3335, 1693, 1592, 1539, 1267, 1138 cm⁻¹; HRMS (EI) *m/z* 421.1879 for M⁺ (421.1889 calcd for C₂₅H₂₇NO₅).

(S)-N-(Benzylloxycarbonyl)-(3-benzylxy-5-methoxy-4-methylphenyl)-glycine (12). A solution of alcohol **11** (248 mg, 0.59 mmol) in acetone (5.0 mL) at 0 °C was added to an aqueous 5% NaHCO₃ (1.5 mL). This colloidal mixture was treated with KBr (10 mg, 0.08 mmol, 0.14 equiv) and TEMPO (98 mg, 0.62 mmol, 1.05 equiv) sequentially. Sodium hypochlorite (2.0 mL, 1.2 mmol, 2.0 equiv, 4-6% chlorine) was added slowly for 10min. The mixture was stirred at 0 °C for 2.5h, and then concentrated *in vacuo*. The residue was treated with H₂O (10 mL) and washed with diethyl ether (2 x 10 mL). The aqueous solution was acidified to pH = 6 with 10% aqueous citric acid solution and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with H₂O (20 mL), brine (20 mL), dried (MgSO₄), and concentrated to give 182 mg (71%) of phenylglycine **12** as a white solid: mp 148-150 °C; R_f = 0.27 (10% MeOH/CHCl₃); [α]²⁵_D +94 (c 1.0, EtOH); ¹H NMR (DMSO-d₆, 300 MHz) δ 12.88 (bs, 1H), 8.06 (d, 1H, J = 8.4 Hz), 7.47-7.31 (m, 10H), 6.84 (s, 1H), 6.72 (s, 1H), 5.09 (d, 1H, J = 8.4 Hz), 5.06 (s, 4H), 3.76 (s, 3H), 2.00 (s, 3H); ¹³C NMR (Acetone-d₆, 50 MHz) δ 172.6, 159.5, 158.5, 156.7, 138.6, 138.2, 136.8, 129.4, 129.3, 128.9, 128.8, 128.7, 128.5, 115.0, 105.5, 104.2, 71.0, 67.1, 59.4, 56.2, 8.8; IR (KBr) 3390, 1740, 1679, 1602, 1542, 1432, 1246, 1142, 1059 cm⁻¹; HRMS (EI) *m/z* 435.1683 for M⁺ (435.1682 calcd for C₂₅H₂₅NO₆).

N-Methyl (2*R*)-2-[(*S*)-1-[((benzylxy)carbonyl)amino]-1-(3-benzylxy-5-methyl-4-methylphenyl)methylcarboxamido]-2-(3,5-dihydroxy-4-methoxyphenyl)ethanamide (14). To a solution of the *N*-methyl azidoacetamide **13** (52 mg, 0.12 mmol) in THF-MeOH (2 mL/2 mL) was added 10% Pd/C (14 mg) and 6N HCl (60 μL, 0.36 mmol, 3.0 equiv). The suspension was stirred under 1 atm H₂ (balloon) for 12h. The mixture was filtered through Celite and evaporated. The residue was chased with anhydrous diethyl ether (20 mL) and dried under vacuum to provide the crude amine hydrochloride as a light green film.

(*S*)-arylglycine **12** (52 mg, 0.12 mmol, 1.0 equiv), HOAt (25 mg, 0.18 mmol, 1.5 equiv), and EDCI (35 mg, 0.18 mmol, 1.5 equiv) were sequentially added to a solution of the above amine hydrochloride in DMF-CH₂Cl₂ (1.5 mL/1.5 mL), followed by TMP (32 μL, 0.24 mmol, 2.0 equiv) at 0 °C. The mixture was stirred at 0 °C for 3h, and then at rt for 17h. The mixture was diluted with EtOAc (30 mL) and washed with 1M NaHSO₄ (2 x 10 mL), saturated aqueous NaHCO₃ (2 x 10 mL), H₂O (10 mL), and brine (20 mL). The organic phase was dried (Na₂SO₄), and concentrated. The residue was purified by flash chromatography (80% → 90% EtOAc/hexanes, gradient elution) to afford 70 mg (91%) of

the dipeptide **14** as a white solid: R_f = 0.56 (1:9 MeOH/CHCl₃); $[\alpha]^{25}_D$ -18.5 (c 0.2, MeOH); ¹H NMR (CD₃CN, 300 MHz) δ 7.42-7.31 (m, 11H), 6.81 (s, 2H), 6.68 (s, 1H), 6.61 (bs, 1H), 6.59 (s, 1H), 6.40 (bs, 1H), 6.24 (s, 2H), 5.21 (d, 1H, J = 7.5 Hz), 5.07-5.05 (m, 3H), 4.97 (s, 2H), 3.71 (s, 3H), 3.68 (s, 3H), 2.63 (d, 3H, J = 4.8 Hz), 2.02 (s, 3H); ¹³C NMR (Acetone-d₆ + CD₃OD, 50 MHz) δ 170.8, 170.2, 158.1, 157.2, 156.2, 137.3, 136.7, 135.9, 135.0, 133.0, 128.0, 127.5, 127.4, 127.3, 127.2, 113.6, 106.4, 103.8, 102.6, 69.7, 66.1, 59.2, 58.6, 56.9, 54.7, 25.0, 7.2; FABHRMS (NBA/PEG246) *m/z* 666.2447 for M⁺ + Na (666.2427 calcd for C₃₅H₃₇N₃O₉Na).

(η⁵-2,4-Cyclopentadien-1-yl) {N-methyl (2*R*)-2-[(*S*)-1-((1*R*, 2*R*)-1-((*tert*-butyloxycarbonyl)amino)-2-((*tert*-butyldimethylsilyloxy)-2-((1,2,3,4,5,6,-h)-4-chlorophenyl)ethylcarboxamido)-1-(3-benzyloxy-5-methoxy-4-methylphenyl)methylcarboxamido]-2-(3,5-dihydroxy-4-methoxyphenyl)ethanamido} ruthenium(II) hexafluorophosphate (16). To a solution of the dipeptide **14** (44 mg, 0.068 mmol) in MeOH/THF (1.5 mL/1.5 mL) was added 10% Pd/C (13 mg) and 6N HCl (34 μ L, 0.21 mmol, 3.0 equiv). The suspension was stirred under 1 atm H₂ (balloon) for 20h. The mixture was filtered through Celite and evaporated. The residue was chased with anhydrous diethyl ether (20 mL) and dried under vacuum to provide the crude amine hydrochloride as a light yellow film. This amine hydrochloride was dissolved in DMF (1.5 mL), and the arylserine-ruthenium complex **15** (60 mg, 0.082 mmol, 1.2 equiv) and HATU (52 mg, 0.14 mmol, 2.0 equiv) was sequentially added at 0 °C. To this was added TMP (20 μ L, 0.15 mmol, 2.0 equiv) and stirred at 0 °C for 3h, and then at rt for 19h. The solution was diluted with CH₂Cl₂ (30 mL) and washed with 1M NaHSO₄ (2 \times 10 mL), saturated aqueous NaHCO₃ (2 \times 10 mL), H₂O (10 mL), and brine (20 mL). The organic phase was dried (Na₂SO₄), and concentrated. The residue dissolved in CH₃CN (0.5 mL) was treated with diethyl ether/hexanes (30 mL/10 mL) and sonicated to precipitate the brown solid for 20 min. This was filtered, washed with diethyl ether (20 mL), and dried to provide 72 mg (92%) of the tripeptide ruthenium complex **16** as a brown powder: ¹H NMR (Acetone-d₆ + CD₃OD, 300 MHz) δ 8.39 (d, 1H, J = 6.6 Hz), 7.93 (d, 1H, J = 4.8 Hz), 7.73 (d, 1H, J = 6.9 Hz), 6.79 (d, 1H, J = 6.0 Hz), 6.62 (d, 1H, J = 6.3 Hz), 6.54-6.43 (m, 6H), 6.20 (d, 1H, J = 5.7 Hz), 5.59 (s, 5H), 5.55 (d, 1H, J = 2.7 Hz), 5.23 (d, 1H, J = 3.0 Hz), 5.18 (d, 1H, J = 6.6 Hz), 4.71 (d, 1H, J = 4.8 Hz), 3.75 (s, 3H), 3.70 (s, 3H), 2.79 (d, 3H, J = 4.5 Hz), 1.98 (s, 3H), 1.38 (s, 9H), 0.96 (s, 9H), 0.27 (s, 3H), 0.18 (s, 3H); ¹³C NMR (CD₃CN, 50 MHz) δ 172.5, 170.8, 169.4, 159.9, 156.9, 156.8, 151.7, 135.9, 135.4, 133.5, 113.5, 108.7, 107.6, 106.3, 105.6, 102.0, 87.6, 87.2, 85.3, 83.8, 83.7, 81.5, 72.1,

62.6, 60.8, 58.9, 58.2, 56.4, 28.4, 27.0, 26.0, 18.4, 8.5, -4.4, -4.8; FABHRMS (NBA/PEG246/NaI) m/z 997.2760 for M^+ - PF_6^- (997.2760 calcd for $C_{45}H_{60}ClN_4O_{11}SiRu$).

N-Methyl (8*R*,11*S*,14*R*,15*R*)-14-[*N*-[(*tert*-Butoxy)carbonyl] amino]-15-(*tert*-butyldimethylsilyloxy)-10,13-dioxo-5-hydroxy-4-methoxy-11-(3-benzyloxy-5-methoxy-4-methylphenyl)-2-oxa-9,12-diazatricyclo-[14.2.2.1^{3,7}]heneicosa-3,4,7(21),16,18,19-hexaene-8-carboxamide (4). To the tripeptide ruthenium complex **16** (40 mg, 0.035 mmol) in DMF (7.0 mL, 5 mM) was added Cs_2CO_3 (57 mg, 0.175 mmol, 5.0 equiv) under argon atmosphere at room temperature. After 4h the mixture was diluted with CH_2Cl_2 (20 mL) and washed with 1M $NaHSO_4$ (2 \times 10 mL), H_2O (2 \times 10 mL), and brine (2 \times 10 mL). The organic phase was dried (Na_2SO_4), and concentrated.

The residue was dissolved in 20 mL of CH_3CN , degassed with Ar for 20 min, and photolyzed (Rayonet, 350 nm) for 24h. The solution was concentrated and purified by chromatography (50 \rightarrow 80% EtOAc/hexanes, gradient elution) to obtain 17 mg (61%) of the cyclized product **4** as a white solid: R_f = 0.42 (80% EtOAc/hexanes); $[\alpha]^{25}_D$ -19.1 (*c* 0.47, MeOH); 1H NMR (Acetone- d_6 , 300 MHz) δ 8.41 (s, 1H), 8.21 (s, 1H), 8.04 (d, 1H, *J* = 9.9 Hz), 7.71 (d, 1H, *J* = 8.1 Hz), 7.46 (d, 1H, *J* = 3.9 Hz), 7.35 (dd, 2H, *J* = 8.4, 2.4 Hz), 7.23 (dd, 2H, *J* = 8.7, 2.1 Hz), 6.95 (dd, 2H, *J* = 8.4, 2.4 Hz), 6.65 (d, 1H, *J* = 1.8 Hz), 6.54 (s, 2H), 5.75 (s, 1H), 5.67-5.63 (m, 2H), 5.34 (bs, 1H), 5.25 (d, 1H, *J* = 7.2 Hz), 4.76 (bs, 1H), 3.98 (s, 3H), 3.79 (s, 3H), 2.67 (s, 3H, *J* = 4.8 Hz), 2.02 (s, 3H), 1.47 (s, 9H), 0.99 (s, 9H), 0.22 (s, 3H), 0.13 (s, 3H); ^{13}C NMR (Acetone- d_6 , 50 MHz) δ 170.3, 169.7, 169.6, 159.8, 157.8, 156.9, 156.8, 155.0, 151.7, 137.7, 137.1, 136.9, 134.7, 129.8, 127.6, 123.7, 123.0, 112.5, 108.9, 107.8, 106.5, 100.6, 80.4, 74.0, 63.0, 61.4, 58.4, 57.5, 56.1, 28.7, 26.5, 26.3, 19.0, 8.5, -4.7, -4.8; FABHRMS (NBA/PEG246) m/z 795.3652 for MH^+ (795.3636 calcd for $C_{40}H_{55}N_4O_{11}Si$).

